Rosetta Launches Next-Generation Cancer Diagnostic, Not Alone in Exploring microRNAs as Biomarkers

A review of the National Cancer Institute's online clearinghouse for clinical trial information shows that more than a dozen groups worldwide are either conducting or preparing to launch studies examining miRNA signatures in humans with a variety of diseases.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.